Clinical Trial Update: Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer [Phase 1]

View source ↗

Summary

This document outlines an ongoing Phase 1 clinical trial evaluating AIC100 CAR T cells in anaplastic thyroid cancer and relapsed/refractory poorly differentiate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Poorly Differentiated Thyroid Cancer

Drugs mentioned

• AIC100 CAR T Cells

Snippet

Sponsor: AffyImmune Therapeutics, Inc. | Conditions: Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING